CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder Market

CDKL5 Deficiency Disorder (CDD) is a rare developmental epileptic encephalopathy (DEE) that is caused by changes (mutations) in the CDKL5 gene. CDD has been classified as a DEE due to the genetic change causes both the epileptic activity and the severe impairment of development. Formerly known as serine/threonine-protein kinase 9 (STK9), CDKL5 stands for cyclin-dependent kinase-like five, and mutations in this gene were first identified as disease-causing. 


Seizures are a significant problem for patients with CDD because they are usually severe and difficult to control with medication. Multiple distinct types of seizures occur and include infantile spasms, myoclonic seizures, and tonic-clonic seizures.


CDKL5 Deficiency Disorder Epidemiological Segmentation 

The Epidemiological Segmentation of CDKL5 Deficiency Disorder in 7MM from 2017 to 2030 is segmented as:- 

  • Prevalence of CDKL5 Deficiency Disorder
  • Diagnosed Prevalence of CDKL5 Deficiency Disorder
  • Gender-Specific Diagnosed Prevalence of CDKL5 Deficiency Disorder
  • Clinical Characteristics of CDKL5 Deficiency Disorder

 

CDKL5 Deficiency Disorder Epidemiology 

  • The total prevalent population of CDKL5 Deficiency Disorder in 7MM in 2017 was 16,397  
  • The total diagnosed prevalence of CDKL5 Deficiency Disorder in males was observed to be 208 whereas, for females, it was 1,315 in the United States in 2017


CDKL5 Deficiency Disorder Market

The market size of CDKL5 Deficiency Disorder in 7MM in 2017 was USD 5.95 Million


CDKL5 Deficiency Disorder Market Drivers

  • Understanding the molecular biology of CDKL5 Deficiency Disorder 
  • Increased Awareness
  • Therapeutic Opportunities
  • The upsurge in Research and Development
  • Research beyond clinical trials 

 

CDKL5 Deficiency Disorder Market Barriers

  • Treatment of Resistant Seizures
  • Fewer Patients
  • Fewer Clinical Trials


CDKL5 Deficiency Disorder Emerging Drugs

The emerging drugs of the CDKL5 Deficiency Disorder market are 

  • Ganaxolone
  • Soticlestat (TAK935/OV935)
  • Fintepla (ZX008)
  • Translarna (ataluren)

And many others.  


CDKL5 Deficiency Disorder Key Players

The key players in the CDKL5 Deficiency Disorder market are

  • Marinus Pharmaceuticals
  • Takeda
  • Ovid Therapeutics
  • Zogenix
  • PTC Therapeutics

And many others.